These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37952003)

  • 1. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.
    Swart M; Kuipers H; Milder F; Jongeneelen M; Ritschel T; Tolboom J; Muchene L; van der Lubbe J; Izquierdo Gil A; Veldman D; Huizingh J; Verspuij J; Schmit-Tillemans S; Blokland S; de Man M; Roozendaal R; Fox CB; Schuitemaker H; Capelle M; Langedijk JPM; Zahn R; Brandenburg B
    NPJ Vaccines; 2023 Nov; 8(1):176. PubMed ID: 37952003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.
    Darricarrère N; Qiu Y; Kanekiyo M; Creanga A; Gillespie RA; Moin SM; Saleh J; Sancho J; Chou TH; Zhou Y; Zhang R; Dai S; Moody A; Saunders KO; Crank MC; Mascola JR; Graham BS; Wei CJ; Nabel GJ
    Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
    Allen JD; Ross TM
    J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes.
    Smatti MK; Nasrallah GK; Al Thani AA; Yassine HM
    Vaccine; 2020 Jan; 38(4):815-821. PubMed ID: 31735504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical optimization of an enterotoxigenic
    Poncet D; Hessler C; Liang H; Gautheron S; Sergent M; Rintala ND; Seydoux E; Huang PD; Argilla D; Ruiz S; Heinrichs J; Maciel M; Orr MT
    NPJ Vaccines; 2020; 5():83. PubMed ID: 32983577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
    Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies.
    Sei CJ; Rao M; Schuman RF; Daum LT; Matyas GR; Rikhi N; Muema K; Anderson A; Jobe O; Kroscher KA; Alving CR; Fischer GW
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34202178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.
    Mittal N; Sengupta N; Malladi SK; Reddy P; Bhat M; Rajmani RS; Sedeyn K; Saelens X; Dutta S; Varadarajan R
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Flynn JA; Weber T; Cejas PJ; Cox KS; Touch S; Austin LA; Ou Y; Citron MP; Luo B; Gindy ME; Bahl K; Ciaramella G; Espeseth AS; Zhang L
    Vaccine; 2022 Jul; 40(32):4412-4423. PubMed ID: 35680500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.